Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

June 4, 2020

Primary Completion Date

July 8, 2023

Study Completion Date

September 28, 2023

Conditions
Solid TumorGastric CancerPancreatic Adenocarcinoma
Interventions
DRUG

AB011 Injection

"Stage 1 Single treatment: AB011 Injection with dose escalation of 1mg/kg up to 40mg/kg, as well as dose expansion with recommended dose level from dose escalation.~Stage 2 Combo Treatment: AB011 combine XELOX( GC) or Gem/nab-P (PC) Injection with dose escalation of 10mg/kg up to 30mg/kg, as well as dose expansion with recommended dose level from dose escalation."

Trial Locations (12)

100142

Beijing Cancer Hospital, Beijing

150081

Harbin Medical University Cancer Hospital, Harbin

200032

Zhongshan Hospital, Zhongshan University, Shanghai

200123

Shanghai East Hospital, Shanghai

230036

Anhui Provincial Hospital, Hefei

276002

Linyi Cancer Hospital, Linyi

310003

The First Affiliated Hospital, Zhejiang University, Hangzhou

310016

Sir Run Run Shaw Hospital, Hangzhou

410008

Xiangya Hospital Central South University, Changsha

418099

Huaihua Second People's Hospital, Huaihua

450003

Henan Cancer Hospital, Zhengzhou

450052

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

Sponsors
All Listed Sponsors
collaborator

Shanghai East Hospital

OTHER

lead

CARsgen Therapeutics Co., Ltd.

INDUSTRY